Name of this trial: SAPHAIRE
What type of cancer is this for? Warm Autoimmune Hemolytic Anemia (wAIHA)
Who is this trial for? Patients with warm autoimmune hemolytic anemia who have failed at 1 least 1 prior line of treatment. Failure, meaning a drop in hemoglobin of ≥ 1g/dL and an increase in LDH levels. Patients must have received a minimum of 4 weeks of other immunosuppression therapy, or 3 months of immunosuppression therapy.
What biomarkers are involved? None
What is the National Clinical Trial #? NCT05786573
Brief summary of this trial: Phase 3, randomized, double-blinded, placebo controlled trial, looking at effect of weekly subcutaneous injection of obexelimab and selected quality of life assessments.
Need to know: Patients will be allowed to continue up to 2 prior failed therapies throughout the 24-week study period, in addition to study treatment.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065